Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + BIIB022
- Development stage
- Phase 1
- Lead developer
- Biogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**sorafenib + BIIB022** is an investigational drug combination consisting of sorafenib, a small molecule multikinase inhibitor, and BIIB022, a non-glycosylated human IgG4 monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R). Sorafenib inhibits several kinases involved in tumor cell proliferation and angiogenesis, notably RAF kinase, VEGF receptors, and PDGF receptor. BIIB022 binds IGF-1R via an allosteric mechanism, blocking signaling without Fc-mediated effector functions, and is believed to inhibit IGF-1R-driven survival and proliferation in cancer cells. The combination was tested in advanced hepatocellular carcinoma but was found not to be tolerable due to dose limiting toxicity at the lowest planned dose[3].
- Brand names
- Nexavar
- Other names
- sorafenib tosylateBIIB-022BIIB022BIIB 022
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)FLT3 (Fms related receptor tyrosine kinase 3)IGF-1R (Insulin-like growth factor 1 receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sorafenib + BIIB022.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + BIIB022.